Drugmakers Push Back Against Proposed Exclusion Criteria for Rare Esophageal Disease Trial

Drug Industry Daily
Two drug companies are pushing back against proposed FDA guidance that would require drug sponsors to hold pre-trials to determine whether patients with a nasty form of esophageal swelling could benefit from an alternate therapy.

To View This Article:


Subscribe To Drug Industry Daily